6-Jan-2026 6:30 AM CST - Business Wire Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President and Co-Chief Executive Officer, will present a corporate overview and a new update on the progress of our organization, includ
4-Nov-2025 6:00 AM CST - Business Wire Summit Therapeutics to Present at Upcoming Investor Conferences $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the following conferences: UBS Global Healthcare Conference in Palm Beach on Monday, November 10, 2025 at 3:30pm EST Jefferies Global Healthcare Conference in Lon
20-Oct-2025 5:45 AM CST - Business Wire Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025. Planned BLA Submission for Ivonescimab in Q4 2025 Today, Summit announces that, based on the results of the HARMONi clinical trial, it plans to submit a Biologics License Application (BLA) in order to seek approval for ivonescimab plus chemotherapy for this proposed in
17-Oct-2025 6:00 AM CST - Business Wire Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III clinical study, HARMONi-GI3, to evaluate ivonescimab plus chemotherapy compared to bevacizumab plus chemotherapy
15-Oct-2025 6:00 AM CST - Business Wire Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data relates to the planned disclosure of the HARMONi-6 clinical trial data. As a reminder, the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispeci
3-Sep-2025 6:00 AM CST - Business Wire Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host a call to discuss the ivonescimab data from our global Phase III clinical trial, HARMONi, presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancers (IASLC) 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona, Spain. The call will be held on Monday, September 8, 2025, at 8:00am ET and will be accessible through our website, w
11-Aug-2025 4:03 PM CST - Business Wire Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2025. Operational & Corporate Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with
5-Jun-2025 7:00 AM CST - Business Wire Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 9, 2025, at 1:20 PM ET. Members of the Summit management team will participate in a fireside chat presentation providing a corporate overview and update on the progress of our organization, including the development of our innovative investigationa
6-Jan-2026 6:30 AM CST - Business Wire Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President and Co-Chief Executive Officer, will present a corporate overview and a new update on the progress of our organization, includ
4-Nov-2025 6:00 AM CST - Business Wire Summit Therapeutics to Present at Upcoming Investor Conferences $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the following conferences: UBS Global Healthcare Conference in Palm Beach on Monday, November 10, 2025 at 3:30pm EST Jefferies Global Healthcare Conference in Lon
20-Oct-2025 5:45 AM CST - Business Wire Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025. Planned BLA Submission for Ivonescimab in Q4 2025 Today, Summit announces that, based on the results of the HARMONi clinical trial, it plans to submit a Biologics License Application (BLA) in order to seek approval for ivonescimab plus chemotherapy for this proposed in
17-Oct-2025 6:00 AM CST - Business Wire Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III clinical study, HARMONi-GI3, to evaluate ivonescimab plus chemotherapy compared to bevacizumab plus chemotherapy
15-Oct-2025 6:00 AM CST - Business Wire Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data relates to the planned disclosure of the HARMONi-6 clinical trial data. As a reminder, the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispeci
3-Sep-2025 6:00 AM CST - Business Wire Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host a call to discuss the ivonescimab data from our global Phase III clinical trial, HARMONi, presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancers (IASLC) 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona, Spain. The call will be held on Monday, September 8, 2025, at 8:00am ET and will be accessible through our website, w
11-Aug-2025 4:03 PM CST - Business Wire Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2025. Operational & Corporate Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with
5-Jun-2025 7:00 AM CST - Business Wire Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 9, 2025, at 1:20 PM ET. Members of the Summit management team will participate in a fireside chat presentation providing a corporate overview and update on the progress of our organization, including the development of our innovative investigationa
